MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.983
AS - Asia 6.395
EU - Europa 4.472
SA - Sud America 953
Continente sconosciuto - Info sul continente non disponibili 226
AF - Africa 106
OC - Oceania 33
Totale 24.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.679
SG - Singapore 2.122
CN - Cina 1.645
IT - Italia 1.121
GB - Regno Unito 947
BR - Brasile 725
HK - Hong Kong 718
VN - Vietnam 641
FI - Finlandia 489
DE - Germania 397
SE - Svezia 391
BD - Bangladesh 389
RU - Federazione Russa 245
FR - Francia 236
KR - Corea 197
UA - Ucraina 149
CA - Canada 139
TR - Turchia 136
NL - Olanda 104
IN - India 95
BG - Bulgaria 89
ID - Indonesia 87
AR - Argentina 86
JP - Giappone 71
MX - Messico 59
AT - Austria 56
IQ - Iraq 54
AE - Emirati Arabi Uniti 36
ES - Italia 35
PL - Polonia 33
EC - Ecuador 32
AU - Australia 30
ZA - Sudafrica 30
IE - Irlanda 29
PK - Pakistan 29
CL - Cile 26
CO - Colombia 26
LT - Lituania 23
MA - Marocco 23
VE - Venezuela 23
BZ - Belize 20
CR - Costa Rica 20
BE - Belgio 18
UZ - Uzbekistan 18
PH - Filippine 17
TH - Thailandia 17
CH - Svizzera 16
KW - Kuwait 14
MY - Malesia 14
PT - Portogallo 14
CZ - Repubblica Ceca 13
NP - Nepal 13
PE - Perù 13
TW - Taiwan 13
HU - Ungheria 12
GR - Grecia 11
JM - Giamaica 11
SA - Arabia Saudita 11
DZ - Algeria 10
KE - Kenya 10
DO - Repubblica Dominicana 9
AZ - Azerbaigian 8
GT - Guatemala 8
KG - Kirghizistan 8
PY - Paraguay 8
EG - Egitto 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
AL - Albania 6
IL - Israele 6
JO - Giordania 6
PR - Porto Rico 6
RO - Romania 6
SV - El Salvador 6
TN - Tunisia 6
EE - Estonia 5
EU - Europa 5
LV - Lettonia 5
NI - Nicaragua 5
IR - Iran 4
SN - Senegal 4
BO - Bolivia 3
BY - Bielorussia 3
CU - Cuba 3
DK - Danimarca 3
GY - Guiana 3
KH - Cambogia 3
LB - Libano 3
MT - Malta 3
NZ - Nuova Zelanda 3
OM - Oman 3
SY - Repubblica araba siriana 3
AG - Antigua e Barbuda 2
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BS - Bahamas 2
CI - Costa d'Avorio 2
Totale 23.908
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.567
Singapore 1.272
Ashburn 1.208
Fairfield 1.026
Hong Kong 709
San Jose 665
Hefei 586
Woodbridge 575
Houston 475
Southend 461
Seattle 445
Chandler 438
Helsinki 433
Council Bluffs 378
Wilmington 325
Cambridge 306
London 293
Beijing 271
Ann Arbor 255
New York 244
Nyköping 235
Ho Chi Minh City 227
Jacksonville 211
The Dalles 209
Dearborn 193
Seoul 193
Los Angeles 191
Modena 181
Munich 147
Milan 138
Hanoi 137
Dallas 117
Chicago 115
Lauterbourg 113
San Diego 110
Moscow 98
Buffalo 94
Princeton 78
Sofia 78
São Paulo 71
Columbus 68
Shanghai 64
Eugene 54
Jakarta 54
Boardman 48
Bologna 48
Rome 44
Nuremberg 42
Salt Lake City 42
Tokyo 40
Amsterdam 37
Izmir 37
Redondo Beach 37
North Bergen 36
Orem 35
Rio de Janeiro 35
Kent 34
Frankfurt am Main 30
Haiphong 30
Redwood City 29
Brooklyn 28
Dublin 28
Toronto 28
Atlanta 26
Florence 25
Da Nang 24
Elk Grove Village 24
Phoenix 24
Montreal 23
Guangzhou 22
Mexico City 22
Reggio Emilia 22
Naples 21
Belize City 20
Vienna 20
Denver 19
Johannesburg 19
Lappeenranta 19
Brasília 18
Brussels 17
Chennai 17
Baghdad 16
Las Vegas 16
Miano 16
Palermo 16
Parma 16
Portsmouth 16
Tashkent 16
Waltham 16
Warsaw 16
Ankara 15
Kilburn 15
Mumbai 15
Quito 15
Boston 14
Halifax 14
Kuwait City 14
Paris 14
San José 14
Belo Horizonte 13
Totale 16.465
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 380
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 351
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 350
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 320
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 317
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 309
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 300
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 296
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 295
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 290
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 286
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 285
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 284
Biotherapies in large vessel vasculitis 281
Imaging of vasculitis: State of the art 280
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 279
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 276
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 273
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 270
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 268
Biologics in vasculitides: Where do we stand, where do we go from now? 267
Increased expression of interleukin-22 in patients with giant cell arteritis 261
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 259
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 256
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 256
Updates on the diagnosis and monitoring of giant cell arteritis 249
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 249
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 244
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 244
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 241
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 241
Tocilizumab for the treatment of giant cell arteritis 236
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 236
Statin use in giant cell arteritis: a retrospective study 235
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 234
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 232
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 232
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 232
Large-vessel giant cell arteritis: a cohort study 227
Mycophenolate mofetil in primary central nervous system vasculitis 226
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 225
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 223
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 221
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 220
Giant Cell Arteritis and Polymyalgia Rheumatica 217
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 215
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 214
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 208
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 206
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 206
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 204
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 204
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 202
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 199
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 198
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 198
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 198
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 196
L30. Assessment of vasculitis extent and severity 191
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 190
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 189
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 188
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 187
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 187
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 183
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 181
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 177
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 175
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 174
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 173
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 173
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 172
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 171
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 171
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 170
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 170
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 167
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 166
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 165
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 163
Development of the Takayasu Arteritis Integrated Disease Activity Index 163
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 160
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 158
What to Know About Biopsy Sampling and Pathology in Vasculitis? 157
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 154
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 153
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 153
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 151
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 149
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 149
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 149
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 147
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 145
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 145
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 145
Eosinophilic giant cell arteritis: A different subset of disease? 145
Role of miR-146a and miR-146b in Giant Cell Arteritis. 144
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 143
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 142
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 141
Totale 21.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.714
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.714
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.218 0 0 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20255.015 138 48 78 342 1.060 826 408 223 534 326 508 524
2025/20269.044 652 414 774 873 960 612 1.203 451 955 684 798 668
2026/20271.141 378 627 136 0 0 0 0 0 0 0 0 0
Totale 24.168